News | Contrast Media | February 06, 2020

Researchers Brighten Path for Creating New Type of MRI Contrast Agent

Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

February 6, 2020 — University of Texas at Dallas researchers are breathing new life into an old MRI contrast agent by attaching it to a plant virus and wrapping it in a protective chemical cage.

The novel strategy is aimed at developing a completely organic and biodegradable compound that would eliminate the need to use heavy metals such as gadolinium in contrast agents, said Dr. Jeremiah Gassensmith, Ph.D., associate professor of chemistry and biochemistry in the School of Natural Sciences and Mathematics and corresponding author of a study published online Feb. 5 in the journal Chemical Science, a publication of the Royal Society of Chemistry.

MRI is a commonly used medical imaging technology that allows physicians to see soft tissues in the body. Some tissues, like cancer, are better seen when a patient is given a contrast agent, which makes diseased parts of the body show up brightly in an MRI scan. The only class of contrast agents approved for use with MRI in the U.S. is based on the heavy metal gadolinium, which is typically excreted through a patient's urine after an MRI is completed.

Because of its widespread use, gadolinium — which is able to sneak through wastewater treatment plants — is increasingly showing up in watersheds in and around large metropolitan areas.

"Gadolinium-based contrast agents are used so much and so often that, just from patients excreting it in their urine, the metal is being released into water resources and sediments," Gassensmith said. "The observed concentrations are still very low, but, nonetheless, it's not exactly clear what effects long-term accumulation of gadolinium might have on the body."

In addition, for patients with compromised kidneys who have difficulty excreting these contrast agents, gadolinium can increase the risk of further kidney damage.

"For these reasons, we wanted to come up with something that was biocompatible and biodegradable, something completely organic with no heavy metals," Gassensmith said. Gassensmith and his colleagues revisited a type of organic radical contrast agent, or ORCA, that had been previously considered as an MRI contrast agent but was abandoned in part because it is not bright enough, and it is broken down too quickly in the body by ascorbate — vitamin C.

"This ORCA is a metal-free agent that is compatible with current MRI techniques, is less toxic to the body and is highly biodegradable. Unfortunately, on its own, it's not very bright, and it's so biodegradable that it's impractical to use," Gassensmith said.

Gassensmith's research group repurposed the agent by first attaching the ORCA molecules to thousands of docking sites on a tobacco mosaic virus.

"Since this is a plant virus, it can't infect people or animals, and it's easily broken down by the liver. Because the virus is so large, it also allows us to put thousands of the ORCA molecules right next to each other," Gassensmith said. "It's the difference between having one Christmas tree light, which is pretty dim, and a whole string of them together, which is quite bright."

The researchers also had to protect the agent so that it would last long enough in the body to be practical for MRI use.

"We put the ORCA in a cage, which no one had done before," Gassensmith said.

Specifically, they fabricated hollow chemical structures called cucurbiturils, so named because they're shaped a bit like a pumpkin (from the plant family Cucurbitaceae), and wrapped them around each ORCA molecule.

"The cage and the contrast agent just sort of stick together -- they don't form a chemical bond with one another," Gassensmith said. "It's similar to the relationship between a key and a lock. Because there is no chemical bond, but the molecules stick together nonetheless, this approach is called 'supramolecular' chemistry, which makes the agent we created a smORCA -- supramolecular macromolecular organic radical contrast agent."

The cage is constructed like a sieve so that water can reach the ORCA. This is necessary because MRIs use the water in the body to create an image. At the same time, the cage blocks larger molecules, like ascorbate, that can inactivate the ORCA.

In mice, the unprotected ORCA broke down within about 30 minutes, while the protected version provided more than two hours of visible contrast.

"Everything we are using has been tested or part of medical research for decades. We just put them all together in a new way," Gassensmith said. "We have some more work to do to show that our material is stable in the complex environment of the human body, and we'd like to see whether we can target it to specific diseases such as cancer and other abnormalities in tissues.

"But I think our results are a promising step toward developing smORCAs into clinically viable contrast agents."

For more information: https://www.utdallas.edu/news/health-medicine/mri-contrast-agent-2020/

 

Related Content of MRI Gadolinium Safety Concerns

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

FDA: No Harm in MRI Gadolinium Retention in the Brain

VIDEO: MRI Gadolinium Contrast Retention in the Brain

Gadolinium May Remain in Brain After Contrast MRI

Related Content

According to Philips, MR-STAT is a major shift in MRI, relying on a new, smart acquisition scheme and machine-assisted reconstruction. It delivers multiple quantitative MR parameters in a single fast scan, and represents a significant advance in MR tissue classification, fueling big data algorithms and AI-enabled integrated diagnostic solutions.

Image courtesy of Philips Healthcare

Feature | Magnetic Resonance Imaging (MRI) | September 21, 2020 | By Melinda Taschetta-Millane
A new report,...
Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
 A cardiac MRI is effective in identifying inflammation of the heart muscle in athletes and can help determine when those who have recovered from COVID-19 can safely return to play in competitive sports, according to a new study by researchers at The Ohio State University Wexner Medical Center.

Getty Images

News | Cardiac Imaging | September 14, 2020
September 14, 2020 — A...
All intensive care unit equipment, including ventilators, pumps, and monitoring devices, as well as the point-of-care magnetic resonance image operator and bedside nurse, remained in the room. All equipment was operational during scanning.

All intensive care unit equipment, including ventilators, pumps, and monitoring devices, as well as the point-of-care magnetic resonance image operator and bedside nurse, remained in the room. All equipment was operational during scanning. Image courtesy of JAMA Neurology

News | Magnetic Resonance Imaging (MRI) | September 11, 2020
September 11, 2020 — A portable, low-field...
Six months after deployment, the no-show rate of the predictive model was 15.9%, compared with 19.3% in the preceding 12-month preintervention period — corresponding to a 17.2% improvement from the baseline no-show rate (p < 0.0001). The no-show rates of contactable and noncontactable patients in the group at high risk of appointment no-shows as predicted by the model were 17.5% and 40.3%, respectively (p < 0.0001).

Weekly outpatient MRI appointment no-show rates for 1 year before (19.3%) and 6 months after (15.9%) implementation of intervention measures in March 2019, as guided by XGBoost prediction model. Squares denote data points. Courtesy of the  American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Artificial Intelligence | September 10, 2020
September 10, 2020 — According to ARRS’
Vantage Galan with Advanced intelligent Clear-IQ Engine (AiCE) provides high-quality images and fast exam times

Coronal orbit images: Left original and right with AiCE.

News | Magnetic Resonance Imaging (MRI) | September 09, 2020
September 9, 2020
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The global pediatric imaging market size is expected to reach $12.2 billion by 2027, registering a CAGR of 7.6% over the forecast period, according to a new report by Grand View Research, Inc.

Getty Images

News | Pediatric Imaging | August 26, 2020
August 26, 2020 — The global ...
AI-Rad Companion Prostate MR for Biopsy Support segments prostate for targeted biopsy under MRI and ultrasound fusion imaging

Image courtesy of Clinica Universidad de Navarra, Spain

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — The Food and Drug Administration (FDA) has cleared two additional...